| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Steven L. Chapman
Also a director
Chief Executive Officer, President and Director
|
46 | Not stated | Not stated | $14,957,319 | |
|
Michael B. Brophy
Chief Financial Officer
|
45 |
Since 2017
9 years
|
Not stated | $5,460,022 | |
|
John Fesko
PRESIDENT, CHIEF BUS. OFFICER
Title from the Form 4 dated Nov 2, 2026
|
46 | Not stated | 2014 | $5,052,790 | |
|
Matthew Rabinowitz
Also a director
Executive Chairman
|
52 | Not stated | Not stated | $11,283,382 | |
|
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER
Title from the Form 4 dated Nov 2, 2026
|
56 | Not stated | 2004 | Not reported | |
|
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS
Title from the Form 4 dated Nov 2, 2026
|
43 | Not stated | 2011 | $5,367,000 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 23, 2026 · updated by the 8-Ks of Jun 5, 2026, Jun 16, 2026, and Jul 6, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Matthew Rabinowitz, Ph.D
Board chair
|
53 |
2005
21 years
|
Not stated | None stated | None stated | Not stated | |
|
Steven Chapman
CEO
|
47 |
2019
7 years
|
Not stated | None stated | None stated | Paid as CEO | |
|
Roelof Botha
Lead independent director
|
52 |
2007
19 years
|
Independent |
Nominating, Corporate Governance and Compliance
|
Block, Inc. | $513,465 | |
|
Rowan Chapman, Ph.D.
|
55 |
2019
7 years
|
Independent |
Human Capital · Chair
|
None stated | Not stated | |
|
Herm Rosenman
|
78 |
2017
9 years
|
Independent |
Audit · Chair
Human Capital
|
DermTech | $501,070 | |
|
Jonathan Sheena
|
53 |
2007
19 years
|
Not stated | None stated | None stated | Not stated | |
|
Roy Baynes, M.D., Ph.D.
|
71 |
2018
8 years
|
Independent |
Nominating, Corporate Governance and Compliance
|
Travere Therapeutics Inc. | Not stated | |
|
Gail Marcus, D.H.A.
|
69 |
2017
9 years
|
Independent |
Nominating, Corporate Governance and Compliance · Chair
|
None stated | $492,020 | |
|
Eric H. Rubin, M.D.
|
67 |
2026
this year
|
Independent |
Nominating, Corporate Governance and Compliance
|
None stated | Not stated | |
|
Ruth Williams-Brinkley
|
74 |
2023
3 years
|
Independent |
Human Capital
|
Travere Therapeutics, Inc. | $429,165 | |
|
Thomas Lynch
Joined Jun 2, 2026
|
- | - | Independent |
Human Capital Committee
|
- | - |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 23, 2026 describes a review policy but reports no transactions.
Read the policy in the proxyLoading...